<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03213002</url>
  </required_header>
  <id_info>
    <org_study_id>17-0312</org_study_id>
    <nct_id>NCT03213002</nct_id>
  </id_info>
  <brief_title>Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM</brief_title>
  <acronym>CAPTEM</acronym>
  <official_title>Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma (GBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of administering the&#xD;
      medication capecitabine along with temozolomide when you start your monthly regimen of oral&#xD;
      temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM).&#xD;
&#xD;
      Capecitabine is an oral chemotherapy that is given to patients with other types of cancer.&#xD;
      The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after&#xD;
      radiation, when taken along with temozolomide. It will also try to determine if the&#xD;
      medication capecitabine helps patients respond to treatment for a longer period of time&#xD;
      compared to just temozolomide alone, which is the standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There were an estimated 22,000 new cases of brain cancers in 2015 in the United States, and&#xD;
      15,000 deaths (Howlader et al., 2014). Glioblastoma (WHO IV), and Anaplastic Astrocytoma (WHO&#xD;
      III), are the most common brain cancers, respectively, representing over 70% of all malignant&#xD;
      gliomas (ABTA, 2015).&#xD;
&#xD;
      Though rare, there is no cure, and the prognosis for these tumors is poor. Survival at 5&#xD;
      years for all CNS cancers is approximately 33.3 % (Howlader et al., 2014). For GBM, the most&#xD;
      lethal of the tumors, with the current standard of care median survival is 14.6 months&#xD;
      (Walid, 2008). Relative survival with GBM at five years is approximately only 5% (Ostrom et&#xD;
      al. CBTRUS 2014).&#xD;
&#xD;
      For newly diagnosed tumors, the current standard of care recommends a multi-modal approach&#xD;
      with surgery to remove the tumor, when possible, followed by 6 weeks of radiation and a&#xD;
      concurrent daily dose of temozolomide (Stupp et al. 2005). This is known as the Stupp&#xD;
      protocol (Stupp et al. 2005). Patients then have a one-month rest period with no treatment,&#xD;
      followed by &quot;maintenance&quot; temozolomide, given five days out of every 28 days, for a minimum&#xD;
      of six months. Some providers keep patients on temozolomide beyond 6 months, or until disease&#xD;
      progression.&#xD;
&#xD;
      Therefore, more therapies are needed to help improve survival, reduce time to recurrence and&#xD;
      improve quality of life for these patients. This trial proposes to improve the current&#xD;
      standard of care by enhancing the efficacy of an active drug temozolomide, currently used for&#xD;
      treatment of GBM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2017</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>PFS will be estimated by calculating the proportion of patients who are alive at 6 months from treatment commencement and are progression-free.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>4 years</time_frame>
    <description>OS will be calculated as the time from treatment initiation to the date of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite overall response rate (CORR) through the Response Evaluation Criteria In Solid Tumors (RECIST)</measure>
    <time_frame>6 months</time_frame>
    <description>Subjects will be classified according to the RECIST criteria, which is a composite of MRI changes, clinical response and changes in steroid use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities will be tabulated and graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03.</measure>
    <time_frame>6 months</time_frame>
    <description>Proportions of subjects experiencing these toxicities will be estimated using standard methods for proportions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Glioblastoma Multiforme (GBM)</condition>
  <condition>Glioblastoma</condition>
  <condition>Glioma of Brain</condition>
  <condition>Glioblastoma, Adult</condition>
  <condition>Brain Tumor</condition>
  <condition>Brain Tumor, Primary</condition>
  <condition>Brain Tumor Adult</condition>
  <condition>Cancer</condition>
  <condition>Brain Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine amd Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Capecitabine at 1500 mg/m2 divided into twice daily dosing, taken on days 1-14, and Temozolomide at 150 mg/m2 - 200 mg/m2 divided into twice daily dosing, taken on days 10-14; days 15-28 off.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine at 1500 mg/m2</description>
    <arm_group_label>Capecitabine amd Temozolomide</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide at 150 mg/m2 - 200 mg/m2</description>
    <arm_group_label>Capecitabine amd Temozolomide</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be capable of giving informed consent.&#xD;
&#xD;
          2. Have a pathology proven diagnosis of any of newly diagnosed Glioblastoma Multiforme&#xD;
             WHO IV&#xD;
&#xD;
          3. Have completed the first part of standard of care chemo-radiation (Stupp), for 6&#xD;
             weeks, and not started the maintenance phase of temozolomide&#xD;
&#xD;
          4. Agree to use effective barrier contraception while on treatment and for 2 months&#xD;
             thereafter, if of childbearing potential&#xD;
&#xD;
          5. Have a life expectancy &gt; 3 months&#xD;
&#xD;
          6. Be between the ages of 18 to 74&#xD;
&#xD;
          7. Have a performance status KPS 70 or greater&#xD;
&#xD;
          8. Be able to swallow pills and capsules&#xD;
&#xD;
          9. Be able to tolerate oral chemotherapeutic medications, with no health threatening&#xD;
             allergies or side effects, based on lab and clinical findings&#xD;
&#xD;
         10. Have adequate bone marrow function, liver function and renal function before&#xD;
             commencing therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior chemotherapy with capecitabine or temozolomide for other prior malignancies.&#xD;
             Patients previously treated with continuous infusion 5-FU or any schedule of DTIC,&#xD;
             which are similar to capecitabine and temozolomide, respectively, will be excluded.&#xD;
&#xD;
          2. Prior chemotherapies for newly diagnosed GBM or AA, other than temozolomide during&#xD;
             radiation.&#xD;
&#xD;
          3. Patients with a history of severe hypersensitivity reaction to capecitabine, 5-FU,&#xD;
             temozolomide (i.e. anaphylaxis or anaphylactic reactions),&#xD;
&#xD;
          4. Serious medical or psychiatric illness preventing informed consent or treatment (e.g.,&#xD;
             serious infection)&#xD;
&#xD;
          5. Prior malignancies in the last 5 years other than curatively treated carcinoma in-situ&#xD;
             previously treated with curative intent (cancer free for the past one year).&#xD;
&#xD;
          6. Performance status, KPS &lt; 70&#xD;
&#xD;
          7. Inability to swallow pills and capsules&#xD;
&#xD;
          8. Concurrent chemotherapy or treatment for the active disease, including devices such as&#xD;
             Optune, high dose vitamin supplements, or any other chemotherapy&#xD;
&#xD;
          9. Patients taking concomitant medications such as Coumadin and phenytoin medications,&#xD;
             need to be excluded because of interactions with capecitabine&#xD;
&#xD;
         10. Patients with previously documented CAD will need to be evaluated by cardiology prior&#xD;
             to start to help risk stratify for capecitabine tolerance&#xD;
&#xD;
         11. Patients with renal insufficiency or hepatic insufficiency&#xD;
&#xD;
         12. Patients with coagulopathies&#xD;
&#xD;
         13. Women who are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Boockvar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lenox Hill Hospital-Northwell Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Boockvar, MD</last_name>
    <phone>212-434-3900</phone>
    <email>jboockvar@northwell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tamika Wong, MPH</last_name>
    <phone>212-434-4836</phone>
    <email>twong4@northwell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lenox Hill Brain Tumor Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamika Wong, MPH</last_name>
      <phone>212-434-4836</phone>
      <email>twong4@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>John Boockvar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Langer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anuj Goenka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Filippi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lalitha Anand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sherese Fralin, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley Ray, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamika Wong, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>John Boockvar, MD Zucker SOM @Hofstra/Northwell</investigator_full_name>
    <investigator_title>Prinicpal INvesigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

